Latest News and Press Releases
Want to stay updated on the latest news?
-
Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in Phase 2 Trial in Smoking Cessation
Demonstrated statistically significant reduction in daily smoking compared to active comparator (p=0.0016) Trial conducted in collaboration with Duke University NEW YORK, April 15, 2019 (GLOBE...
-
Builds on preclinical research conducted at Duke University and clinical research conducted by Axsome Smoking cessation is the third indication for AXS-05 Phase 2 trial initiation anticipated in the...